Opus Genetics (IRD) Revenue (2010 - 2026)

Opus Genetics (IRD) has 8 years of Revenue data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Revenue fell 50.64% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $12.0 million, a 12.22% decrease from a year earlier, with the FY2025 full-year figure at $14.2 million, up 29.15% from the prior year.
• Revenue for Q1 2026 stood at $2.2 million, down from $3.9 million in the prior quarter.
• Over the last five years, Revenue for IRD reached as high as $39.8 million in Q4 2022 and fell as low as $1.1 million in Q2 2024.
• Historically, Revenue has averaged $6.2 million across 5 years, with a median of $3.4 million in 2023.
• Across the five-year window, Revenue tumbled 95.76% in 2023 and jumped 159.17% in 2025, its largest moves.
• Year by year, Revenue stood at $39.8 million in 2022, then tumbled by 95.76% to $1.7 million in 2023, then surged by 154.41% to $4.3 million in 2024, then slipped by 10.16% to $3.9 million in 2025, then plunged by 44.19% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $2.2 million in Q1 2026, $3.9 million in Q4 2025, and $3.1 million in Q3 2025.